Search PubMed⌕ Search

Biomedical subjects

A Lassus

Publications and source records attributed to A Lassus.

190 records · Page 11Linked to original sources
PubMedDate not supplied

Combination of laser-therapy with 0.5% idoxuridine cream in the treatment of therapy-resistant genital warts in male patients: an open study.

Forty heterosexual male patients with therapy resistant penile warts of long duration (mean 12.9 months) were treated with carbon dioxide laser, immediately followed by topical application of 0.5% idoxuridine cream twice daily for 14 days. In case of incomplete or no response to the initial treatment, the treatment procedure was repeated once. All patients had previously been repeatedly treated with podophyllotoxin 0.5% solution and/or carbon dioxide laser surgery. After two weeks of treatment, 32 patients (80%) were completely healed. The remaining eight patients were retreated and four weeks after the start of the study 35 patients (87.5%) showed complete response. Three months after the study had been initiated 34 patients (85%) were still completely healed. No adverse reactions were observed. It was concluded that laser surgery followed by topical application of 0.5% idoxuridine cream for two to four weeks seems to be highly effective in the treatment of longstanding, therapy-resistant genital warts in men. Because of the uncontrolled nature of the present study and the relatively small number of patients treated, it would be important to carry out controlled studies in larger study populations and to carry out a follow-up examination of at least six months after treatment.

Adult↗
PubMedDate not supplied

A comparative study of topical analgesia with a lidocaine/prilocaine cream (EMLA) and infiltration anesthesia for laser surgery of genital warts in men.

Treatment of genital warts by laser surgery was performed in 100 male patients under local infiltration (2-6 ml 1% Xylocaine) or topical anesthesia with 2.5-7.5 ml EMLA cream. EMLA cream was applied to the warts ten minutes before the operation. Pain was significantly less during application of EMLA than during infiltration of Xylocaine. Infiltration anesthesia resulted in better surgical analgesia than EMLA, although the difference was small. The combined pain scores of application and surgery were significantly smaller in the EMLA group. The result suggests that EMLA applied for ten minutes constitutes a less painful treatment and is thus the anesthetic of choice for the laser surgery of genital warts.

Adolescent↗
PubMedDate not supplied

Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis.

A total of 80 patients with chronic, stable psoriasis, 34 of whom also had psoriatic arthritis, were treated with 1122 mg/day eicosapentaenoic acid ethyl ester and 756 mg/day docosahexaenoic acid ethyl ester. Before the study and after 4 and 8 weeks of treatment a Psoriatic Association scoring index (PASI) score was assessed. Before treatment the mean PASI score was 3.56, after 4 weeks 1.98 and after 8 weeks 1.24; the decrease in the score was highly significant (P less than 0.001). The degree of pruritus decreased most rapidly, followed by scaling and induration of the plaques, and erythema was most persistent. At the end of the trial, seven patients were completely healed and in 13 other patients more than 75% healing was observed but in 14 patients the result was poor. The majority of patients with psoriatic arthritis reported a subjective improvement in joint pain during the study. It is concluded that polyunsaturated ethyl ester lipids may be useful for the treatment of psoriasis and psoriatic arthritis and may provide an important adjuvant to standard therapy of both conditions.

Adult↗
PubMedDate not supplied

A double-blind study comparing oleum horwathiensis with placebo in the treatment of psoriasis.

The efficacy and tolerability of topically applied oleum horwathiensis were evaluated in a double-blind, placebo-controlled study of 42 patients with chronic stable psoriasis. Both groups of patients, 19 receiving oleum horwathiensis treatment and 23 receiving placebo treatment for 12 weeks, showed clinically significant effects of treatment. Oleum horwathiensis was more effective than placebo throughout the treatment period but the difference was not statistically significant at any time. No changes in laboratory values attributable to treatment were recorded. The symptoms of the oleum horwathiensis-treated group continued to be less severe than those of the placebo-treated group throughout the 12 weeks of follow-up. The follow-up period, however, occurred partly during the summer and since the clinical status of the patients may have been affected by climate the difference between the treatment groups was not analysed statistically. The tolerability and cosmetic acceptance of oleum horwathiensis were remarkably good, and good clinical efficacy in scalp lesions--which was not the subject of this study--was spontaneously reported by several patients.

Administration, Topical↗
PubMedDate not supplied

Imedeen for the treatment of degenerated skin in females.

Imedeen, a new compound for oral administration consisting of special protein fractions and some glucosaminoglycans extracted from marine fish, has been shown in previous pilot studies to have a repairing effect on sun-damaged skin. In an open study, 10 females with sun-damaged skin, aged 39-61 years, were treated with 0.5 g/day Imedeen for 90 days. At baseline and after 30, 60 and 90 days, the following parameters were clinically evaluated: wrinkles; mottles; dryness of skin; and brittleness of hair and nails. After 90 days' treatment all signs of sun-damage had improved and brittleness of hair and nails was normalized in all cases. These clinical observations were confirmed by changes in skin thickness and elasticity. In a second double-blind study, 30 females in the same age range and with similar signs of sun-damage were treated with 0.5 g/day Imedeen or placebo for 90 days. The results in the Imedeen-treated group corresponded to those in the first study whereas no response to treatment was observed in the placebo treatment group.

Administration, Oral↗
PubMedDate not supplied

Colloidal silicic acid for oral and topical treatment of aged skin, fragile hair and brittle nails in females.

In an open study, women with biologically aged skin and fragile or thin hair, or brittle nails were treated orally with 10 ml colloidal silicic acid (Silicol) once daily for 90 days and applied colloidal silicic acid to the face for 10 min twice daily. Of the 50 subjects treated, three withdrew from treatment after 30 days because of excessive drying of the facial skin due to topical application. In the remaining 47 subjects there was statistically significant improvement in the thickness and turgor of the skin, wrinkles and condition of the hair and nails. The number of mottles also declined, but the change was not statistically significant. Ultrasound measurements did not detect any statistically significant change in the thickness of the epidermis or elasticity of the skin, but there was a significant increase in the thickness of the dermis.

Administration, Oral↗
PubMedDate not supplied

The effect of silicol gel compared with placebo on papulopustular acne and sebum production. A double-blind study.

Altogether 30 patients (19 females and 11 males), mean age 19 years, were divided randomly into two groups. All patients had chronic papulopustular acne of the face. A total of 15 patients were treated topically with Silicol gel for 20 min twice daily for 6 weeks and the remaining 15 patients were treated with a placebo gel in a similar fashion. A clinical evaluation was carried out at baseline, and after 2, 4 and 6 weeks of treatment. The clinical variables evaluated were as follows: number of comedones, papules, pustules and cysts on a standard area of the left cheek (area 5 x 5 cm) and measurement of sebum production on the same area by the use of Sebumeter SM 810 PC (Courage and Khazaka, Ltd, Germany). No concomitant treatment was allowed during the study period. One patient using Silicol gel withdrew after 2 weeks of treatment because of severe irritation of the facial skin, leaving 29 patients who could be evaluated. In the active group, the number of comedones decreased from a mean of 48.5 to 15.1 after 6 weeks of treatment. The corresponding figures for papules were 10.7 and 1.0, for pustules 6.8 and 0, and for cysts 0.6 and 0. In the placebo group no improvement could be observed. There was a highly significant difference in efficacy between the two groups (P < 0.001) in favour of the actively treated group. The mean sebum index was 193 at baseline and 88 after 6 weeks. Correspondingly in the placebo group the mean sebum index at baseline was 187 and after 6 weeks 179. This difference between the two groups was also statistically significant (P < 0.001). After a short follow-up period (3 months) no deterioration was observed in the 14 'active' patients, showing either complete cure or improvement.

Acne Vulgaris↗
PubMedDate not supplied

Colloidal silicic acid for the treatment of psoriatic skin lesions, arthropathy and onychopathy. A pilot study.

In a randomized, double-blind study, patients with chronic plaque-type psoriasis were either treated with 30 ml colloidal silicic acid gel, orally, daily, and topically with the same gel (n = 15), or were treated identically with placebo gel (n = 15) for 3 months. One stable psoriatic lesion on the knee or elbow was treated topically and followed throughout the study. Five patients in the treated group and seven controls had psoriatic arthropathy and 11 treated patients and 12 controls had psoriatic onychopathy. Three treated patients and six controls withdrew because of skin irritation or lack of efficacy. In the treated group there were clear improvements in scaling, induration and erythema after treatment. The nail changes were cured in five of 10 evaluable patients in the treated group and joint pain was reduced by almost half in the four evaluable patients with arthropathy. There were no such improvements in the placebo group.

Administration, Oral↗
PubMedDate not supplied

[What is STD?].

Explore the source record for details and available documents.

Female↗